Compare BTAI & YQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTAI | YQ |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 22.2M |
| IPO Year | 2018 | 2020 |
| Metric | BTAI | YQ |
|---|---|---|
| Price | $0.07 | $3.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 11.2M | 69.8K |
| Earning Date | 05-08-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $1.68 |
| 52 Week High | $3.19 | $6.45 |
| Indicator | BTAI | YQ |
|---|---|---|
| Relative Strength Index (RSI) | 19.82 | 59.07 |
| Support Level | N/A | $3.28 |
| Resistance Level | $1.22 | $3.68 |
| Average True Range (ATR) | 0.06 | 0.43 |
| MACD | -0.07 | 0.13 |
| Stochastic Oscillator | 0.57 | 57.65 |
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.